Early RA Treatment Proves Beneficial

NOVEMBER 01, 2004

Researchers have found that early, aggressive treatment with a combination of disease-modifying antirheumatic drugs (DMARDs) provides long-term benefits for individuals with rheumatoid arthritis (RA). The study involved 160 participants in the early stages of RA who were treated with 3 different DMARDs or conventional single-DMARD therapy. During the Finnish study, the participants were assessed 5 years after taking part in a clinical trial.

The study results, reported recently in Arthritis & Rheumatism, found that, after 5 years, the participants who received triple-combination- DMARD therapy showed a 28% remission rate, compared with a 21% remission rate among individuals in the single-DMARD group. The participants in the combination group reported less swelling pain and mobility. Furthermore, they had dramatically less RA-related joint damage in their hands and feet.

The researchers pointed out that long-term effects were witnessed only in the participants who received combination-DMARD treatment soon after the RA diagnosis. On the other hand, those who started on single-DMARD therapy and later took combination-DMARD therapy did not have the same results.



SHARE THIS SHARE THIS
0
 

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.